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ABSTRACT
EVALUATION OF ANTHELMINTIC PROPERTIES AND TOXICITY OF PURE COMPOUNDS
ISOLATED FROM DALEA SPP (PLANTAE, FABACEAE).

by
Victoria LH McPherson
November 26, 2018
Infecting upwards of a billion people worldwide, hookworm is one of the most
prevalent parasitic infections affecting the world today. Those infected experience
hookworm disease, characterized by severe anemia, which can lead to malnutrition,
low birth weights, and physical and mental impairments. Currently, the
benzimidazoles albendazole and mebendazole are used as the primary treatment;
however, resistance to these drugs is emerging. Due to this resistance, finding new
anthelmintic compounds active against hookworm is a priority. Previously, a pure
compound isolated from Dalea ornata was identified as having strong anthelmintic
activity when used against the hookworm Ancylostoma ceylanicum. This project was
continued using pure compounds isolated from Dalea pogonathera and D. parryi.
The pure compounds were tested for toxicity and anthelmintic properties. The
structure of these compounds were determined using NMR. To test toxicity, spleen
cells were obtained from Golden Syrian hamsters, Mesocricetus auratus, which were
then exposed to 50µg/mL of compound for 24 hours to determine whether the
compound induces apoptosis. This was done by analyzing the cells after the 24 hour
iii

incubation using flow cytometry to compare cell survival from the experimental cells
to the controls. An ex vivo assay was employed to test for anthelmintic properties by
exposing adult A. ceylanicum to 50µg/mL of compound for 5 days, monitoring
motility and mortality. Unfortunately, none of the pure compounds tested were
active towards A. ceylanicum; however, the methods used can be replicated for
similar projects.
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CHAPTER 1
INTRODUCTION
Hookworm Epidemiology
Hookworm is one of the most prevalent parasitic infections in the world
today. Infecting an estimated billion people worldwide, hookworm is an endemic
infection in Africa, China, Southern Asia, and South America, with 240 million people
being infected in Sub-Saharan Africa alone (Hotez et al. 2004; Brooker et al. 2010).
Furthermore, an estimated 5.08 billion people are at risk, with 1 billion of those
being school-aged children (Pullan and Brooker 2012). These infections are
responsible for around 4 million disability adjusted life years (DALYs) and an
economic loss of up to $139 billion dollars (Bartsch et al. 2016). The hookworm
species responsible for causing these infections in humans are Necator americanus
and Ancylostoma duodenale, with occurrences of a zoonotic infection of
Ancylostoma ceylanicum (de Silva et al. 2003; Hotez et al. 2004; Brooker et al. 2010;
Ngui et al. 2012). Depending on the worm burden, specifically the number of adult
worms residing in the small intestine, the infection can cause hookworm disease,
which is characterized by its primary symptom of iron-deficiency anemia (Guyatt et
al. 2000; Crompton and Nesheim 2002; Humphries et al. 2011). This anemia is
caused by hookworms feeding on blood while it resides in the host’s small intestine.
The adult hookworm latches on to the endothelial cells of the small intestine via its
buccal capsule and creates negative pressure to feed off of the flow of blood and
plasma, producing anticoagulant secretions that inhibit the function of platelets
1

(Cappello et al. 1996, Chadderdon and Cappello 1999, Del Valle et al. 2003). If the
amount of blood lost is greater than that which is being produced, the end result is
anemia and hypoproteinemia, an abnormally low level of protein in the blood
(Crompton and Nesheim 2002).
The most at risk for this infection are those living in poverty with minimal
sanitation (Hotez 2008; Humphries et al. 2011). This disease is spread rapidly
through communities because it is primarily transmitted through contact with soil
contaminated by feces, although, for Ancylostoma species an oral route of
transmission can occur (Ngui et al. 2012). Although all people living in poverty in an
endemic area are at risk for the disease, children and pregnant women are the most
at risk for complications associated with hookworm disease. Iron-deficiency anemia
and hypoproteinemia are associated with stunting growth both physically and
mentally in children (Sakti et al. 1999; Guyatt et al. 2000), malnutrition (Crompton
and Nesheim 2002; Hotez et al. 2004), and pregnancy complications such as low
birth weight and impairment of milk production (Santiso 1997). Although mortality
rates for hookworm infection are low, there have been a few studies suggesting
chronic hookworm infection increases the susceptibility of the host to other
infections such as malaria (Mwangi et al. 2006; Humphries et al. 2011), tuberculosis
(Potian et al. 2011), and HIV (Borkow et al. 2007; Walson and John-Stewart 2007).
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Hookworm Life Cycle
While residing in the small intestine, female hookworms produce
approximately 30,000 eggs per day, varying with species, which then leave the body
in feces. The eggs hatch, the larvae molt twice, and then become infective during
their third stage (L3). At this stage they produce proteases allowing them to
penetrate the skin (Loukas et al. 2005), most commonly being the palms of hands
and the soles of feet, get into the blood stream, and make their way to the lungs.
While in the lungs, the L3 are coughed up into the trachea, swallowed, and then
arrive at the small intestine. This is where the larvae mature into adult hookworms,
feed, release eggs, and begin the cycle once more (Figure 1). During the act of
feeding, adult hookworms continue to be motile in the small intestine, moving every
4-6 hours after feeding at a single spot, resulting in a blood loss of about 0.02-0.2 mL
of blood per worm per day (Sakti et al. 1999). This loss of blood can result in the
primary symptom of hookworm disease, iron-deficiency anemia.

3

Figure 1.1. The Life Cycle of Hookworm.
Depicted is the life cycle of hookworm, starting at the egg released in the feces (1)
until the maturation from larva to adult worm in the small intestine (CDC 2013). Not
pictured is the second route of infection, oral transmission.

Hookworm Immunology
As with most pathogens, hookworm infection elicits an immune response. To
clear a hookworm infection, it is necessary for the adaptive immune response to be
activated, which involves the maturation of CD4+ T lymphocytes. Specifically, a T
helper 2 (TH2) response is required. A TH2 response is one of the subsets of the
adaptive immune response characterized by the activation and differentiation of B
cells into plasma cells. Plasma cells have the ability to produce and secrete antigen
specific antibodies, proteins that can bind to antigens and activate other cells of
immunity. To successfully clear a hookworm infection, IgE must be produced and
basophils, eosinophils, and mast cells need to be activated (Quinnell et al. 2005;
4

Loukas et al. 2005; McSorley and Loukas 2010; Urb and Sheppard 2012). In response
to a hookworm infection, interleukin-4 (IL-4) is secreted by basophils that have
either acquired antigen or in the presence of dendritic cells acting as antigen
presenting cells, initiating a TH2 response by causing the differentiation of naïve T
cells to TH2 cells while also preventing a TH1 dominant response (Gaze et al. 2012;
Yoshimoto 2018). A TH1 response is not necessary and would not aid in hookworm
clearing because it involves the activation of macrophages, phagocytic cells, that are
unable to engulf hookworm due to their large size. The activated TH2 cells then
secrete IL-5 and IL-13, which activate eosinophils and facilitates the secretion of IgE
respectively (Gaze et al. 2012). Secreted IgE will then bind to the hookworm antigen
using the variable region of its structure, leaving the constant region (Fc) to be
bound by eosinophils or mast cells. Once bound, eosinophils and mast cells will
release cytokines and reactive oxygen species that are toxic to the hookworm and
eventually result in death. This immune response generally occurs in the blood,
during the larval hookworm’s migration. Once in the small intestine, the antibody
IgA contributes to the mucosal immune response. Involved with protecting mucosal
surfaces, such as the small intestine, IgA is potentially responsible for the
neutralization of hookworm secretions, initiation of eosinophil degranulation, and
can interfere with hookworm feeding (Bungiro et al. 2008; Moreau and Chauvin
2010).
However, hookworm does have methods to evade the immune system. One
of the first evasion tactics employed is antigenic shedding. It is believed that
5

hookworm larva is covered in a larval sheath that they cast once they have infected
a host to distract the immune system (Kumar and Pritchard 1992). Instead of
preventing an immune response, it uses the distraction of an immune response to
complete the migration to the small intestine. Although the mechanism is not
known, it has also been shown that hookworm reduce dendritic cell differentiation
and suppresses the proliferation of antigen presenting cells in general (Dondji et al.
2008; Passos et al. 2017). As mentioned previously, dendritic cells are integral to the
activation of the adaptive immune system and, by preventing their differentiation,
the immune response is slowed. Hookworm also has been shown to suppress and
induce apoptosis in CD4+ T cells (Chow 2000; Dondji et al. 2010; Morawski et al.
2017). Another way hookworm disrupts the TH2 response is to induce Natural Killer
cells (NK cells). This induction allows NK cells to produce interferon-γ, which is a
cytokine involved with the upregulation and maintenance of a TH1 response
(Bethony et al. 2006). Besides preventing a TH2 response from occurring, hookworm
can also reduce the effect of a TH2 response. One of the mechanisms behind this is
the production of proteases. Hookworms have been shown to produce proteases
that cleave the Fc region of antibodies (Pritchard 1995). This means that the
antibodies can bind to the antigen, but not allow the activation of eosinophils or
mast cells, thereby saturating the antibody binding regions with ineffective
antibodies. Hookworm can also produce metalloproteases, which cleave eotaxin, a
protein that recruits eosinophils to the site of infection (Culley et al. 2000). Along
with proteases, hookworm also release excretory/secretory (ES) proteins. These
6

proteins have been shown to induce a hookworm-like immune response, even when
hookworm is not present. They upregulate nitric oxide production, which impacts
lymphocyte proliferation, IL-12, and interferon-γ, while decreasing IgG and IL-4,
impairing the TH2 response (Dondji et al. 2008; Diliani and Dondji 2017). ES is also
hypothesized to induce a specific dendritic cell phenotype, one that is tolerogenic
(Logan et al. 2018). Tolerogenic dendritic cells, specifically CD103+ dendritic cells,
are responsible for maintaining homeostasis in the intestinal mucosa. They are
induced by the production of IL-10 from TH2 T cells and activate FoxP3+ T regulatory
cells (Treg). The primary function of tolerogenic dendritic cells and Treg cells is to
modulate the immune system by immunosuppression. Essentially, they produce
anti-inflammatory cytokines like those of IL-10 and TGF-β that prevent the
differentiation and proliferation of naïve T cells into effector T cells (Ricci et al.
2011). Related to this is the activation and polarization of M2 macrophages.
Damaged epithelial cells release IL-33, which propagates Treg and M2 macrophage
differentiation, to begin immunosuppression and a healing response (Gordon and
Martinez 2010; Takenaka and Quintana 2017; Schwartz et al. 2018). By activating
cells of immunity involved in suppression, hookworm prevent an immune response
by invoking self-tolerance. This mechanism of enforcing self-tolerance is one of the
reasons those chronically infected with hookworm do not have allergies. This effect
is also amplified in the lungs during larval migration, which is hypothesized to be the
mechanism responsible for the decrease in asthma in those infected (Schwartz et al.
2018). Lastly, as previously mentioned, hookworm needs a steady flow of blood to
7

feed. To do this, they produce anticoagulants to inhibit and prolong the period of
time it takes for blood to clot (Schuster et al. 2013).

Current Treatment Methods
Current treatment of hookworm infection is completely reliant on the use of
benzimidazole anthelmintics, specifically mebendazole (MBZ) or albendazole (ABZ),
distributed following the deworming campaigns endorsed by the World Bank and
World Health Organization (WHO 2001; World Bank 2003). These campaigns call for
mass drug administration to high-risk groups (school-aged children). Although cure
rates following single dose regiments previously were recorded as high as 100%,
newer studies suggest this number is much lower, with a failure rate of 39-56%
(Humphries et al. 2011; Humphries et al. 2013). A recent study conducted by
Palmeirim et al. compared a single dose treatment of 500mg to three doses of
100mg mebendazole against soil-transmitted helminths. The cure rate of the single
dose treatment was drastically lower, 13%, compared to the 97.9% cure rate of the
multiple dose treatment (Palmeirim et al. 2018). Unfortunately hookworm was not
present as one of the soil-transmitted helminths included in this clinical trial.
However, in a study including hookworm, the cure rate was 25.5% for a single dose
of 500mg mebendazole (Mrus et al. 2018). With the need to use multiple doses,
concerns have been raised about the selective pressure put on hookworm and
potential resistance arising from it. This is significant especially given the high failure
rates of recent field studies, suggesting resistance may be emerging (Furtado et al.
8

2016).
Using MBZ and ABZ may treat the infection, but they do not provide lasting
immunity to hookworm infection. This means that even if the treatment is
successful, the rate of re-infection still remains high (Albonico et al. 1995). This is
why an attempt at a hookworm vaccine occurred, to decrease the rate of reinfection (Hotez et al. 2013). However, despite the high hopes for the success of the
trial, the vaccine trial was halted due to the allergic reactions occurring in those
previously exposed to hookworm after administration. The same research group has
recently modified the vaccine by changing the target. Instead of using a larval
protein, the vaccine target is now an adult hookworm protein belonging to N.
americanus, Glutathione – S – Transferase (Na-GST-1) (Diemert et al. 2017). It is
important to note that the vaccine target does differ from MBZ and ABZ’s target.
The benzimidazoles prevent the formation of microtubules which prevents or
minimizes the uptake of glucose. Without glucose, the hookworm is unable to
produce ATP and eventually dies. The Glutathione – S – Transferase on the other
hand targets the feeding behavior of hookworm by preventing the detoxification of
reactive oxygen species. Hookworms digest blood by breaking it down into smaller
molecules such as heme and hematin. Both of these molecules can generate
reactive oxygen species which are toxic to the hookworm (Diemert et al. 2017). If
successful, this vaccine would treat hookworm rather than prevent larval migration.
Another vaccine in development is a cysteine protease inhibitor K11777, which has
shown a promising effect in increasing the mortality of larvae and adult A.
9

ceylanicum hookworms (Vermeire et al. 2016).

Anthelmintic and Antiparasitic Natural Products
Using natural products to treat infection and disease is not a novel concept.
There is evidence that natural products have been used in ancient civilizations such
as the Egyptians and Mesopotamians, with the earliest written record of plant-based
therapies dating back to 2600 BCE (Dias et al. 2012). Currently, around 80% of the
world’s population is reliant on natural products for their primary healthcare (Ekor
2013). Along with general malaise, plant compounds have also been used to treat
parasitic infections. Artemotil, a derivative of artemisin, is a compound isolated from
Artemisia annua that has anti-malarial properties (Dias et al. 2012). Also belonging
to the Artemisia family, Artemisia parviflora and Artemisia siversiana have
anthelmintic properties active against the nematode Haemonchus contortus. At
12.5mg/mL, the A. parviflora extract killed over 60% of adult worms and over 50% of
L3 larva. At 25mg/mL, the A. siversiana extract killed over 60% of adult worms and
L3 larva (Irum et al. 2017). Another compound found to have anthelmintic
properties is in Eucalyptus globulus, which has activity against nematodes in goats.
Using a 7.5mg/kg dosage, a 66% reduction in the fecal egg count was recorded 21
days post-treatment (Kanojiya et al. 2015). Lastly, an extract from Combretum
mucronatum was active against Caenorhabditis elegans, a non-pathogenic
nematode, causing a mortality rate of 58% at 1mg/mL (Agyare et al. 2014). Dalea
spp. are plants of interest due to their already documented medicinal properties,
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such as D. versicolor’s ability to enhance the activity of antibiotics against resistant
bacterium (Belofsky et al. 2004) and D. elegans’ antioxidant properties (Elingold et
al. 2008). A recent study published from the Dondji and Belofksy labs at Central
Washington University indicated that tephrosin, a Dalea ornata isolate, had
anthelmintic properties against the hookworm Ancylostoma ceylanicum (Table 1).
After exposing adult worms to 25µg/mL of tephrosin (compound 10), all were dead
after 72 hours (Deardorff et al. 2016). However, tephrosin is also highly toxic,
making it unusable as a therapy for now. To continue this project, compounds
isolated from Dalea parryi and Dalea pogonathera were evaluated for anthelmintic
properties and toxicity.
Table 1.1. Ex Vivo Anthelmintic Activity of D. ornata Compounds 1-10 Toward A.
ceylanicum.
With a concentration of 25µg/mL, compound 10, tephrosin, had killed 97% of
hookworms after 48 hours. By 72 hours, all of the worms were dead (Deardorff et al.
2016). Through this experiment, Tephrosin exhibited anthelmintic properties and
was very active against A. ceylanicum.
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CHAPTER 2
THE EVALUATION OF TOXICITY AND ANTHELMINTIC PROPERTIES OF PURE
COMPOUNDS ISOLATED FROM DALEA POGONATHERA

12

ABSTRACT
Infecting around 1 billion people, hookworm is one of the most prevalent
parasitic infections. Chronic infection can lead to severe anemia, malnutrition, and
increased susceptibility to other infections. The current treatments used are the
benzimidazole derivatives, mebendazole and albendazole. Although previously
successful, emerging resistance has been reported and the need to identify new
anthelmintic compounds is high. Pure compounds were isolated from Dalea
pogonathera using various techniques such as vacuum liquid and thin layer
chromatography. The structure of these compounds were then identified using NMR
and used in toxicity assays to determine whether they induced apoptosis in the
spleen cells of Golden Syrian hamsters, Mesocricetus auratus. Of the 16 compounds
tested at 50μg/mL, 7 were non-toxic and the remaining 10 ranged from slightly toxic
to toxic. The compounds were also tested in an ex vivo assay to determine if
anthelmintic properties were present. Monitored for motility and mortality at
50μg/mL for five days, none of the 16 compounds were significantly active against
adult Ancylostoma ceylanicum.
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Being one of the most prevalent parasitic infections to date, hookworm
infects roughly a billion people worldwide. It is endemic in Africa, Southern and
Southeast Asia, and Central and South America, with an increasing prevalence in
areas of rural poverty.1 The hookworms Necator americanus, Ancylostoma
duodenale, and Ancylostoma ceylanicum are those responsible for the majority of
human infections; however, there are some accidental infections most commonly
associated with dog hookworms such as Ancylostoma caninum.2-6 When infected,
the hosts release feces containing eggs that will hatch in a warm and moist
environment, releasing larva. The larva will then undergo two molts, becoming the
infective L3 larva. The L3 are able to pierce through the skin, use the bloodstream to
travel to the lungs where it causes irritation. This irritation causes the host to cough,
bringing the larva into the trachea where it is then swallowed, eventually bringing
them to the small intestine where the L3 mature into adult hookworms. As adults,
the hookworms latch onto the endothelial cells lining the small intestine using their
buccal capsules and feed off the flow of blood and plasma, producing anticoagulant
secretions that inhibit the function of platelets.6-10 During the act of feeding, adult
hookworms continue to be motile in the small intestine, moving every 4-6 hours
after feeding at a single spot, resulting in a blood loss of about 0.02-0.2 mL of blood
per worm per day.10 Depending on the hookworm burden, this can cause anemia,
the primary symptom of hookworm disease.11 A. duodenale and A. ceylanicum also
have an oral route of transmission, involving the direct ingestion of L3 larva from the
environment.
14

Although all living in endemic areas are at risk for infection, those living in
poverty have an increased prevalence of disease.12,13 The most at risk for
complications are pregnant women and children. Iron-deficiency anemia and
hypoproteinemia are associated with stunting growth both physically and mentally
in children, malnutrition, and pregnancy complications such as low birth weight and
impairment of milk production.1,10,11,14,15 Chronic infection is also associated with
reduced lymphocyte proliferation and increased apoptosis of CD4+ T cells and an
increase in nitric oxide production.16-18 More recently, hookworm and other soiltransmitted helminths have been discovered to activate tolergenic dendritic cells, T
regulatory cells, and M2 macrophages.19-23 All of these cell types promote selftolerance, inhibiting the immune response. This regulation of the immune response
may be responsible for the increased susceptibility of those chronically infected to
tuberculosis, HIV, and malaria.13,24-27
Currently, the primary drugs used to treat hookworm infection are the
benzimidazole derivatives, mebendazole (MBZ) and albendazole (ABZ). Following the
World Health Organization and World Bank’s deworming campaign, the mass drug
administration of single-dose MBZ and ABZ were widely distributed to high-risk
groups.28,29 Although cure rates following single dose regiments previously were
recorded as high as 100%, newer studies suggest this number is much lower, with a
failure rate of 39-56% seen in field studies.13,30 A recent study conducted by
Palmeirim et al. compared a single dose treatment of 500mg to three doses of
100mg mebendazole against soil-transmitted helminths. The cure rate of the single
15

dose treatment was drastically lower, 13%, compared to the 97.9% cure rate of the
multiple dose treatment.31 Unfortunately hookworm was not present as one of the
soil-transmitted helminths included in this clinical trial. However, in a study including
hookworm, the cure rate was 25.5% for a single dose of 500mg mebendazole. 32 With
the need to use multiple doses, concerns have been raised about the selective
pressure put on hookworm and potential resistance arising from it.33 This is
significant especially given the high failure rates of recent field studies, suggesting
resistance may be emerging.13,30,31 New potential candidates with a different
mechanism of action than the benzimidazoles are desirable.
Dalea, a plant genus belonging to the Fabaceae family, is native to the New
World. Dalea spp. have been previously shown to have medicinal purposes such as
increasing the activity of antibiotics and antioxidant properties.35,36 Tephrosin, a
pure compound isolated from Dalea ornata, is very active against adult A.
ceylanicum, causing the mortality of all of the worms by day three of an ex vivo
trial.34 However, tephrosin is also toxic, making it unusable as a therapy for now.
Due to the identification of an active compound, Dalea spp. are still of interest. To
continue this work, Dalea pogonathera, native to Arizona, New Mexico, and Texas,
has been evaluated for the presence of anthelmintic isolates.

Results and Discussion
After the D. pogonathera extracts were purified via linear solvent gradient
chromatography (Figure 1), two bioassays were completed to determine the toxicity
16

against splenocytes acquired from Golden Syrian hamsters, Mesocricetus auratus,
and evaluate the anthelmintic properties towards A. ceylanicum.

Figure 2.1. Structures of D. pogonathera Compounds 1-11, 16

17

Table 2.1. Toxicity of D. pogonathera Compounds 1-16 at 50μg/mL
Relative to No Treatment Control
%
% control
compound
compound
toxicity
live cells
live cells
1
47.2
33.1
Non-toxic*
2
0.31
40.5
Toxic*
3
0.31
40.5
Toxic*
4
7.65
29.8
Toxic*
5
24.7
38.6
Toxic*
6
34.8
34.1
Non-toxic
7
0.66
34.9
Toxic*
8
0.13
34.9
Toxic*
9
9.3
36.5
Toxic*
10
0.4
36.5
Toxic*
11
0.53
36.5
Toxic*
12
0.17
36.5
Toxic*
13
44.9
52.2
Non-toxic
14
51
52.2
Non-toxic
15
55.5
52.2
Non-toxic
16
77.2
66.9
Non-toxic*
*Statistically significant difference

Comparing the percentages of live cells of 106 cells of the 50μg/mL treated wells to
that of the no treatment wells containing 2% DMSO using flow cytometry, the
toxicity of each compound was determined (Table 1). The toxicity, for the context of
this paper, is defined as the percentage of live cells in the experimental wells being
statistically significantly lower than the percentage of live cells from the control
wells. Compounds 1, 6, and 13-16 were all non-toxic, with compounds 1 and 16
actually performing significantly better than the control, acting potentially as
mitogens. The reason for this increased percentage of live cells was not investigated;
however, all of the compounds that were non-toxic are promising potential
18

therapies. The remaining compounds were found to be toxic, with some, like
compounds 2 and 12, devastatingly so, with a percentage of live cells of 0.31% and
0.17% respectively.
All of the compounds were then tested using an ex vivo assay to evaluate the
anthelmintic properties the compounds had towards adult A. ceylanicum (Table 2,
Figure 1). Unfortunately, none of the compounds exhibited any significant
anthelmintic activity. Compound 4 had the most activity with a mean mortality rate
of 87.5%, followed by compound 8 with 91.7% (±7.2).
Table 2.2. Ex Vivo Anthelmintic Activity of D. pogonathera Compounds 1-16 toward
A. ceylanicum
% survival of A. ceylanicum relative to control at 50μg/mL
compound
day 1
day 2
day 3
day 4
day 5
1
100
100
100
100
100
2
100
100
100
100
100
3
100
100
100
100
100
4
100
100
100
100
87.5 (±0)
5
100
100
100
100
91.7 (±14.4)
6
100
100
100
100
100
7
100
100
100
95.8 (±7.2) 91.7 (±7.2)
8
100
100
100
100
100
9
100
100
100
100
100
10
100
100
100
100
100
11
100
100
100
100
100
12
100
100
100
100
95.8 (±7.2)
13
100
100
100
100
95.8 (±7.2)
14
100
100
100
100
100
15
100
100
100
100
95.8 (±7.2)
16
100
100
100
100
100
aData in the table are in mean values ± standard error.
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Figure 2.2. Percent Survival of Hookworm on Day 5 of Ex Vivo.
Although none of the compounds isolated from D. pogonathera were active
toward A. ceylanicum, the methods used are applicable for similar research involving
the screening of compounds. Aside from the biological components, compounds 4
and 8 are novel compounds that have not been structurally identified or added to
databases before. It would be interesting to investigate whether these compounds
have other medicinal properties not tested in the scope of this paper despite their
toxicity.
Being considered one of the World Health Organization’s neglected tropical
diseases, the need to identify new compounds active toward hookworm is great and
more research in developing treatments is necessary, such as the work toward a
hookworm vaccine.37 Not only is this work relevant to areas of high prevalence, but
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also to the recently reported reemergence of hookworm in the Southern United
States.38 Hookworm effects over a billion people at a given time, identifying a new
active compound is just one step toward eradicating hookworm disease.

Experimental Section
Plant Material. Whole plants of D. pogonathera were collected by G. Belofsky in
Southeast Arizona.
Extraction and Isolation. The aerial portions of D. pogonathera were extracted using
methanol, blended, filtered, and the filtrates were evaporated. The crude extract
was then fractionated using vacuum liquid chromatography and Sephadex LH-20
chromatography. The fractions created were pooled using thin layer
chromatography. To separate these fractions into pure compounds, linear solvent
gradient chromatography was used. 13C NMR spectroscopy was used to determine
structure and confirm that each compound obtained was unique.
Animals. All animals used in the following experiments were Golden Syrian hamsters
(Mesocricetus auratus) housed at Central Washington University (CWU), with some
being obtained from Simonsen Laboratories (Gilroy, CA, USA). The experiments
conducted were approved by the CWU Institutional Animal Care and Use Committee
(Protocol Number A021706).
Toxicity Assay. The spleens of euthanized Golden Syrian hamsters were collected
and cells were obtained using cell strainers. The cell preparation was then deprived
of red blood cells using lysis buffer and spun in the centrifuge for 10mins, 1200RPM
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at 4°C. The cells were washed in RPMI-5 [5% heat inactivated fetal calf serum, 1%
penstrep (100μg/mL penicillin/streptomycin), 1% L-glutamate (100μg/mL Lglutamate), RPMI-1640] twice, with the cells being spun between each wash. After
the washes, the cells were counted and 106 cells were plated in RPMI-10 [10% heat
inactivated fetal calf serum, 1% penstrep (100μg/mL penicillin/streptomycin), 1% Lglutamate (100μg/mL L-glutamate), RPMI-1640] in each well of a 24-well plate. They
were then exposed to a 50μg/mL dose of the pure Dalea pogonathera compounds.
The positive control used was 5mM menadione, a known toxic compound, and the
negative control was 2% DMSO.39 The experiment was run in triplicate with
additional wells for the no-treatment and assay stain controls. The cells were
incubated for 24 hours in 37°C, 5% CO2 and then prepared for flow cytometry
analysis. They were stained with Invitrogen’s (Carlsbad, CA, USA) annexin V, Alexa
Fluor 488 conjugate and propidium iodide and run through the Bio-Rad S3e Cell
Sorter, collecting 50,000 events. The data was then compensated to minimize the
overlapping of fluorophores, without which can cause the skewing of data due to
the overexpression of fluorescence detected by the flow cytometer, and analyzed
using FlowJo (Ashland, OR, USA) software. In FlowJo, the data used for further
analysis was the percent of cells not dyed. The only cells of concern were those still
living and cells dyed by either annexin V or propidium iodide are dead or in the
process of dying. Following this, a one-way ANOVA with a post-hoc Tukey
comparison was completed to determine toxicity by comparing the percentage of
living cells from treated wells to the no-treatment control.
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Ex Vivo Assay. 3-6 week old Golden Syrian hamsters were infected with 125 - 150 L3
hookworms. During the 21-day infection, fecal collections were done to collect eggs
to maintain the lifecycle of A. ceylanicum. After 21 days, the hamsters were
euthanized via CO2 and the adult hookworms were removed from the small intestine
and washed as previously described.34 Following the three 15 minute washes, the
worms were incubated for 24 hours at 37°C, 5% CO2 in RPMI-1640 supplemented
with 50% fetal bovine serum, 25μg/mL fungizone, and 20X penicillin/streptomycin.
The hookworms were then plated in 24-well plates with 8 - 10 worms per well
containing RPMI-1640, 50% fetal bovine serum, 25μg/mL fungizone, 20X
penicillin/streptomycin, and 50μg/mL of the Dalea pogonathera compound being
tested. To avoid bias, one worm was plated per well to each well before adding
another, with the pattern of addition changing after each complete cycle. The
positive control used was 25μg/mL tephrosin, a D. ornata compound that was
shown to be highly active against adult hookworm34, and the negative control was
1% DMSO. The plated worms were incubated at 37°C, 5% CO2 for 5 days with
monitoring of mortality and motility daily. Motility was scored on a scale from 0 to 3,
with 3 being normally active and 0 being dead. Percent mortality was calculated by
counting the number of dead, 0 motility, worms. The resulting data were analyzed
by one-way ANOVA with a post-hoc Tukey comparison to determine if the
compound had any significant anthelmintic activity toward A.ceylanicum.
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CHAPTER 3
INVESTIGATION OF DALEA PARRYI (FABACEAE) METABOLITES FOR
ANTHELMINTIC ACTIVITY AGAINST THE HUMAN PATHOGENIC
HOOKWORM ANCYLOSTOMA CEYLANICUM.
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ABSTRACT
Hookworm, a parasite infecting a billion people worldwide causing iron-deficiency
anemia, has begun to exhibit resistance to the current treatments used, the
benzimidazoles mebendazole and albendazole. Due to this emerging resistance, the
identification of new anthelmintic compounds is necessary. Using a combination of
vacuum liquid chromatography and Sephadex LH-20 chromatography and other
purification techniques, 13 pure compounds were isolated from Dalea parryi. The
structures of these compounds were determined using HRESIMS, 13C NMR, and
DEPT. Of the 13 compounds, only 12 had enough material for biological testing. The
12 compounds were then tested for their toxicity towards lymphocytes obtained
from Golden Syrian hamsters, Mesocricetus auratus. Using flow cytometry, the
percentage of living cells from cells treated with 50μg/mL of compounds for 24
hours was compared to cells with no treatment. Of the 12 compounds tested, 4
were non-toxic, with the remaining 8 being significantly toxic. An ex vivo assay was
also conducted to determine the presence of anthelmintic properties. Adult
hookworms were exposed to 50μg/mL of compounds for 5 days, with motility and
mortality being monitored daily. Unfortunately, none of the compounds were
significantly active.
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Infecting around 1 billion people worldwide, hookworm is a parasitic worm
endemic to Africa, Central and South America, and Southern and Southeast Asia
causing iron-deficiency anemia.1,2 Although generally not fatal, chronic hookworm
infection has been linked to an increased susceptibility to malaria, tuberculosis, and
HIV, malnutrition, and physical and developmental stunting in children.1,2,3,4
Infection with hookworm occurs when exposed skin comes into contact with
the infective stage larva (L3) located in the soil. L3 pierce the skin and use the host’s
bloodstream to travel to the lungs. While in the lungs, the larva causes irritation,
causing the host to cough and swallow, bringing the larva up the trachea and on to
the small intestine. While in the small intestine, the hookworm mature into adults
and attach to the small intestine, producing anticoagulants to continuously feed off
blood.3,5-8 Although varying between species, about 0.02-0.2 mL of blood per worm
per day is lost.3 This blood loss is responsible for the primary symptom of hookworm
disease, iron-deficiency anemia.
Currently, following the deworming campaigns put forth by World Bank and
the World Health Organization, the mass drug administration of the benzimidazoles
albendazole and mebendazole are the usual treatment method for hookworm.10,11
Previously recorded single-dose cure rates were as high as 100%; however, recent
field studies refute that, with a cure rate of around 39-56%.9,12 Multiple dose
regiments have more success, with a recent study suggesting a cure rate for soiltransmitted helminths at 97.9%.13 Due to the increase in dosages, concerns have
been raised about the selective pressure put on hookworm and the potential for
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emerging resistance.14 Research in identifying new compounds with anthelmintic
properties to eventually replace albendazole and mebendazole is integral to the
continued treatment of hookworm disease.
Prior research using Dalea ornata was successful in identifying a compound
with anthelmintic properties, tephrosin.15 However, tephrosin is toxic, so it is unable
to be used as a therapy for now. To continue this work, pure compounds have been
isolated from D. parryi, which has never been the subject of chemical investigation,
and they have been evaluated for their toxicity and anthelmintic properties.

Results and Discussion

Chemical Investigation. The D. parryi crude methanol extracts were tested in an ex
vivo bioassay that revealed apparent reductions in survival of A. ceylanicum
hookworm. At 100 g/mL, the crude extracts of aerial and root portions exhibited
13% and 10% reductions in survival, respectively, at day 5 of the assay. This level of
activity is quite low compared to that of the crude extract of aerial parts of D.
ornata; >50% reduction in survival on day 2.15 However, it was expected that activity
would increase with further purification, as was the case in that prior study. The
crude extracts of D. parryi were each fractionated by silica gel vacuum liquid
chromatography (VLC) and selected materials from these columns were further
separated by Sephadex LH-20 chromatography. Successive stages of purification of
compounds over silica gel using linear gradients and step-gradient elution, resulted
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in thirteen pure compounds (Figure 1). Of these compounds, 9 of them are new
compounds.

Figure 3.1. Structures of Compounds 1-12 Isolated from Dalea parryi.

Biological Investigation. After the 24 hour incubation of cells exposed to 50μg/mL of
compound, cell survival was determined using flow cytometry. The percentage of
live cells in wells with exposure to compound was compared to the control cells
exposed to 2% DMSO and were determined to be toxic if the difference, after a oneway ANOVA with a post-hoc Tukey comparison, was statistically significant. Of the
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12 compounds tested, compounds 4, 7, 9, and 13 were found to be non-toxic (Table
1). The remaining compounds were toxic with compounds 5 and 6 having the most
destructive effect on the splenocytes. Following the toxicity assay, an ex vivo with
adult hookworm being exposed to 50μg/mL of compound for 5 days was conducted.
The mortality and motility was monitored daily. Unfortunately, none of the 12
compounds tested had any significant anthelmintic properties (Table 1). The lowest
percent survival was compound 2 at 83 (+ 3.5). Although compounds 5 and 6 were
very toxic to mammalian cells, the percent survival of hookworm was 96 (+ 5.3) and
100 (+ 0.0) respectively, demonstrating that the toxicity toward splenocytes is not
indicative of activity toward hookworm.
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Table 3.1. Ex Vivo Anthelmintic Activity of D. parryi Compounds 1-2, 4-13 toward
A. ceylanicum Hookworm.

Compound

1
2
4
5
6
7
8
9
10
11
12
13

% Survival of A.
ceylanicum relative to
controla
after five days of
compound exposure
at 50 μg/mL
93 (+ 6.7)
83 (+ 3.5)
88 (+ 7.0)
96 (+ 5.3)
100 (+ 0.0)
88 (+ 4.6)
100 (+ 0.0)
100 (+ 0.0)
100 (+ 0.0)
100 (+ 0.0)
88 (+ 7.0)
88 (+ 7.0)

Toxicity expressed as
negative or positive effects on
splenocyte survival relative to
100% survival (centerline)b

a

Controls of medium plus 1% DMSO all exhibited >95% survival
at day five. Data are in mean values ± standard error (SE).
b Flow cytometric analyses….+ error ranges.
Although none of the compounds exhibited activity toward hookworm, the chemical
investigation and identification of 9 new compounds is relevant in continued
hookworm research. The methods used are applicable to similar projects and will
hopefully serve its purpose in identifying new compounds to eventually replace
albendazole and mebendazole.

Experimental Section
General Experimental Procedures. Melting points were measured on an SRS
MPA160 DigiMelt apparatus. Optical rotations were recorded on a PerkinElmer 341
polarimeter (Na lamp, 589 nm); concentrations are reported in g/100 mL. UV spectra
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were recorded on an HP-Agilent 8453 photodiode array instrument. ECD spectra
were obtained on an Aviv Biomedical, Inc. M400 circular dichroism spectrometer
using dry MeOH as the solvent and a 0.1 cm path length quartz cuvette. IR spectra
were recorded on a Bruker Alpha spectrometer with universal Alpha T attachment.
NMR spectra were obtained on a Bruker Avance 400 MHz system with Topspin 1.3
software. HRESIMS data were recorded on a Waters Q-TOF Premier hybrid mass
spectrometer. A Waters Acquity UPLC was used to inject samples in 1:1 MeCN−H2O
using flow injection analysis (100 μL/min) with no intervening column. Preparative
linear gradient chromatography employed a custom two-chamber apparatus
creating a continuous gradient, with gravity flow (~20 mL/min), over 70-230 mesh
silica gel. This was connected to glass columns of varying sizes sealed with PTFE endfittings. Samples were preadsorbed onto silica gel in solution and evaporated to
dryness prior to loading onto the column. Eluting solvent percentages given (see
‘Preparation of the extracts and compound purification’) represent estimates, for the
sake of reproducibility, of the solvent compositions entering the column. Collection
of 20 fractions (20 mL) for example, with a linear gradient of EtOAc (0-100%) in
hexanes, will result in fraction 10 having a composition of ~50% EtOAc. Silica gel
step-gradient columns also employed 60-100 mesh silica gel, and were run with
preadsorbed samples. TLC plates (Sigma-Aldrich; silica gel 60, F254) were eluted with
mixtures of MeOH in CH2Cl2 or of EtOAc in hexanes, and visualized with UV (254 nm)
and the spray reagent vanillin/H2SO4 (1 g/100 mL w/v) followed by gentle heating.
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Plant Material. Whole plants of D. parryi were collected by G. Belofsky, V. Belofsky,
and L. Belofsky on April 22, 2015 about two miles up the East End Trail of McDowell
Regional Park, Arizona, USA, at GPS coordinates N 33º 40.584′, W 111º 48.157′, alt.
3404 ft. A voucher specimen was authenticated by Dr. Tom Cottrell, Department of
Biological Sciences, Central Washington University, and was deposited in the
herbarium of the same department, accession no. 2015005GB. Plant parts were
separated, the roots were washed with distilled water and dried briefly, while aerial
portions (leaves, stems, and flowers) were air-dried for several days. Dry aerial
portions and roots were powdered in a Waring blender and stored in vacuum-sealed
plastic bags at -20 ºC prior to extraction.
Preparation of Extracts and Compound Purification. Powdered roots (112 g) and
aerial portions (1150 g) of D. parryi were extracted separately with 1.5 L and 7 L of
MeOH, respectively, in a Waring blender for 2-3 min. The mixtures were each
filtered, and the filtrates were evaporated under reduced pressure resulting in 14.9
g of root extract and 135.0 g of aerial portion extract.
The crude root extract was preadsorbed in MeOH solution onto ∼10 g of silica
gel, the solvent removed under vacuum, and the resulting powder subjected to VLC
over a prepacked column bed (10 × 5 cm; i.d. × h) of TLC-grade (230−400 mesh) silica
gel. The column was eluted using a stepwise gradient of solvents beginning with
hexanes (1 L) and continuing with mixtures (0.75 L each) of EtOAc in hexanes (20, 40,
60, 80, and 100% EtOAc), followed by mixtures of MeOH in CH2Cl2 (2, 5, 8, 10, and
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30% MeOH). Fractions 3-4 (2.14 g) from this column expressed both the heaviest
weight and greatest mixture complexity by TLC analysis. These were further
separated by Sephadex LH-20 (Sigma-Aldrich) column chromatography (2.5 × 50 cm)
eluting with 1 L of 3:1:1 hexanes-toluene-MeOH, followed by 1 L of 100% MeOH at a
flow rate of 0.3-0.5 mL/min with ~8 mL per fraction. The glass column was equipped
with a male luer tip for connection to a 100 tube, drop-counting fraction collector.
Materials of similar composition as determined by TLC were pooled to give 49
fractions. Compounds 1-10 were all isolated upon elaboration of selected
subfractions of these Sephadex LH-20 column fractions.
The resulting Sephadex LH-20 fraction 3 (166 mg) was further purified over silica
gel (10 × 2.5 cm) using a linear gradient (see ‘General Experimental Procedures’) of
EtOAc (0-10%) in hexanes. Fractions eluting with ~3-5% EtOAc resulted in 1 (89 mg).
The combined Sephadex LH-20 fractions 5-6 (61 mg) were further purified over silica
gel (5 × 2.5 cm) using a linear gradient of EtOAc (0-20%) in hexanes. Fractions
eluting with 20% EtOAc afforded 2 (23 mg). Combined Sephadex LH-20 fractions 1521 (45 mg) were further purified over silica gel (9 × 2.5 cm) using a linear gradient of
EtOAc (0-30%) in hexanes. Fractions eluting with ~9-12% EtOAc resulted in 9 (8 mg),
while later fractions from this column, eluting with 15-30% EtOAc were further
purified over silica gel (1.5 × 5 cm) using a step-gradient (see ‘General Experimental
Procedures’) of EtOAc (0-100%) in hexanes to yield 3 (6 mg) in one fraction, eluting
with 30% EtOAc. Fractions 45 and 46 of the Sephadex LH-20 column were combined
(51 mg) and chromatographed over silica gel (8 × 2.5 cm) using a linear gradient of
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EtOAc (0-50%) in hexanes. Final purification of fractions from this column (14 mg)
that eluted with 25-30% EtOAc was achieved over silica gel (1.5 × 6 cm) using
isocratic elution with 30% EtOAc in hexanes to provide 4 (7 mg). Fraction 25 from
the Sephadex LH-20 column (204 mg) was further purified over silica gel (10 × 2.5
cm) using a linear gradient of EtOAc (0-15%) in hexanes. Fractions eluting with ~811% EtOAc resulted in 5 (139 mg). Pooled fractions 38-40 from the Sephadex LH-20
column (41 mg) were further purified over silica gel (7 × 2.5 cm) using a linear
gradient of EtOAc (0-25%) in hexanes. Fractions eluting with ~13-20% EtOAc
resulted in 6 (11 mg). Fraction 14 from the Sephadex LH-20 column (19 mg) was
further purified over silica gel (8 × 1.1 cm) using a linear gradient of EtOAc (0-15%) in
hexanes. Fractions eluting with ~1-6% EtOAc afforded 7 (5 mg). Fractions 42-44 of
the Sephadex LH-20 column were combined (89 mg) and chromatographed over
silica gel (10 × 2.5 cm) using a linear gradient of MeOH (0-6%) in CH2Cl2. Materials
from this column that eluted with ~2-3% MeOH (75 mg) were chromatographed
over silica gel (11 × 2.5 cm) using a linear gradient of EtOAc (0-30%) in hexanes.
Fractions eluting with ~23-29% EtOAc (51 mg) were purified over silica gel using a
step-gradient of EtOAc (0-30%) in hexanes to yield 8 (38 mg) in fractions eluting with
20-22% EtOAc. Compound 10 (10 mg) was obtained by chromatography of
Sephadex column fraction 34 over silica gel (10 × 2.5 cm) using a linear gradient and
eluting with ~11-14% EtOAc in hexanes.
The crude extract of the aerial portions (135 g) was preadsorbed in MeOH
solution onto ∼15 g of silica gel, the solvent removed under vacuum, and the
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resulting powder subjected to VLC over a prepacked column bed (10 × 7 cm; i.d. × h)
of TLC-grade (230−400 mesh) silica gel. The column was eluted using a stepwise
gradient of solvents beginning with hexanes (2 L) and continuing with mixtures (1 L
each) of EtOAc in hexanes (20, 40, 60, 80, and 100% EtOAc), followed by mixtures of
MeOH in CH2Cl2 (2, 5, 8, 10, and 30% MeOH). Fractions of interest 5-7 (2.7 g) from
this column were further separated by Sephadex LH-20 column chromatography (2.5
× 75 cm) in an otherwise identical manner to that described above for the root VLC
fractions, resulting in 25 fractions. Compound 11 (6 mg) was obtained by
chromatography of Sephadex column fraction 14 (64 mg) over silica gel (7 × 2.5 cm)
using a linear gradient and eluting with ~42-48% EtOAc in hexanes. A VLC column of
Sephadex fraction 23 (85 mg) over silica gel (5 × 3.5 cm) eluting with 100 mL
fractions of increasing EtOAc in hexane afforded 12 (16 mg) in a fraction that eluted
with 75% EtOAc. Sephadex fractions 15-16 (97 mg) were chromatographed over
silica gel (12 × 2.5 cm) using a linear gradient of 0-6% MeOH in CH2Cl2. Material that
eluted with ~3% MeOH was then purified over silica gel (4.5 × 1.5 cm) using a stepgradient of 0-100% EtOAc in hexanes. Fractions eluting with 60-70% EtOAc
consisted of 13 (5 mg).
Anthelmintic and Toxicity Assays. Syrian hamsters (Mesocricetus auratus) were
used for all animal work including maintenance of the hookworm Ancylostoma
ceylanicum in the laboratory, ex vivo and toxicity assays. Hamsters were either
purchased from Simonsen Lab (Gilroy, CA, USA) or second generation bred at the
Central Washington University animal facility. Animals were housed in 12:12 hour
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light: dark and temperature-controlled conditions at the Central Washington
University (CWU) animal facility. Animal handling and experimental conditions
followed protocols approved by the CWU Institutional Animal Care and Use
Committee (Protocol Numbers A111608, A111609, and A021706). For each round of
the ex vivo assay, 20-25 hamsters were orally infected with 125-150 L3 (infectious
stage) hookworm larvae. Initial A. ceylanicum larvae were generously provided by
Dr. Michael Cappello (Yale School of Medicine, New Haven, CT). On day 21 PI, the
fecal material was gathered, the hamsters were euthanized and the small intestines
were collected. The fecal material contains hookworm eggs and was used for the
production of more infectious larvae for subsequent experiments. Adult worms
were harvested from the intestine using tweezers under a dissecting microscope and
processed as previously described.15 Briefly, worms were placed in a Petri dish
containing phosphate buffer saline (PBS) with 20 X penicillin/streptomycin
(pen/strep), and fungizone (25 μg/mL). The worms were washed three times in RPMI
medium containing fungizone (25 μg/mL) and 20X penicillin/streptomycin. After an
overnight incubation (37oC; 5% CO2) in RPMI medium supplemented with fungizone
(25 μg/mL) and 20X penicillin/streptomycin, and 50% fetal bovine serum (FBS),
active worms were randomly placed in a 24-well tissue culture plate. Each wells
contained 8-10 worms. Each compound was tested in triplicate. 1% DMSO was used
in negative control wells while tephrosin, a highly active compound isolated earlier
from D. ornata was used as positive control.15 All the compounds were tested at 50
μg/mL except the tephrosin positive control that was tested at 25 μg/mL. Plant
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materials dissolved in 100% DMSO were diluted in RPMI, fungizone (25 μg/mL), 20X
penicillin/streptomycin medium, and 50% FBS medium to reach a final concentration
of 1% DMSO. Plates were checked daily for 5 days to determine the percent survival
of worms. Dead and living worms were counted to calculate percent survival.
In order to evaluate the potential safety of compounds extracted to mammalians,
toxicity assays were conducted. Splenocytes from Golden Syrian hamsters were
collected and plated in RPMI-10 (RPMI medium supplemented with 10% heat
inactivated fetal calf serum, penicillin/streptomycin and L-glutamine) in a 24-well
plate. Cells were then exposed to 50μg/mL of the pure Dalea parryi compounds. The
positive control used was 5mM menadione, This compound has been shown to be
toxic to cells by inducing DNA damage via reactive oxygen species formation.16 2%
DMSO was used negative control in the toxicity evaluations. Samples and controls
were run in triplicate. Each well contained 106 splenocytes. The cells were incubated
for 24 hours at 37°C, 5% CO2 and then prepared for flow cytometry. They were
stained with annexin V, Alexa Fluor 488 conjugate and propidium iodide (Thermo
Fischer Scientific, Waltham, MA). Stained cell parameters were acquired by flow
cytometry using the Bio-Rad S3e Cell Sorter (Bio-Rad Laboratories, Hercules, CA).
The flow cytometry data were analyzed and analyzed using the FlowJo software
program (Treestar, Ashland, OR).
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